v3.25.1
Balance Sheet Components
 12 Months Ended
Mar. 31, 2025
Balance Sheet Related Disclosures [Abstract]  
Balance Sheet Components Balance Sheet Components
Prepaid Expense and Other Current Assets
Prepaid expense and other current assets consisted of the following:
March 31, 2025March 31, 2024
(in thousands)
Prepaid expenses$8,827 $7,896 
Insurance receivables18,497 2,188 
Advances to employees3,101 — 
Other receivables1,379 3,563 
Other current assets2,826 1,794 
Prepaid expenses and other current assets$34,630 $15,441 
Property and Equipment, Net
Property and equipment, net consisted of the following:
March 31, 2025March 31, 2024
(in thousands)
Computer equipment and software$2,713 $7,347 
Laboratory equipment and software34,681 34,539 
Furniture and office equipment836 7,416 
Leasehold improvements967 31,250 
Capitalized asset retirement obligations— 853 
Property and equipment, gross39,197 81,405 
Less: accumulated depreciation and amortization(37,939)(58,906)
Property and equipment, net$1,258 $22,499 
Depreciation and amortization expense was $4.6 million, $7.8 million and $10.6 million for the fiscal years ended March 31, 2025, 2024 and 2023, respectively. For the fiscal years ended March 31, 2025 and 2024, the Company wrote off fully depreciated property and equipment, which is no longer in use, with a cost basis of $11.7 million and $4.5 million, respectively. In connection with the Chapter 11 Cases and the abandonment of the Sunnyvale Facility (as defined below), the Company wrote off leasehold improvements and recorded impairment losses of $16.5 million within restructuring and other charges in the consolidated statements of operations and comprehensive loss for the fiscal year ended March 31, 2025. The Company also disposed of certain computer equipment and software, furniture and office equipment and recorded gain on disposal of property and equipment of $0.4 million within general and administrative expense in the consolidated statements of operations and comprehensive loss for the fiscal year ended March 31, 2025. There were no impairments to property and equipment for the fiscal year ended March 31, 2024, and only an immaterial impairment for the fiscal year ended March 31, 2023.
Operating Lease Right-Of-Use Assets, Net
Operating lease right-of-use assets, net consisted of the following:
March 31, 2025March 31, 2024
(in thousands)
Operating lease right-of-use assets2,408 56,662 
Less: accumulated amortization(1,875)(18,533)
Operating lease right-of-use assets, net533 38,129 
See Note 12, "Leases" for information related to impairment to ROU assets from continuing operations.
Internal-Use Software, Net
Internal-use software, net consisted of the following:
 March 31, 2025March 31, 2024
 
(in thousands)
Capitalized internal-use software$41,633 $35,918 
Less: accumulated amortization(22,237)(15,402)
Internal-use software, net$19,396 $20,516 
During the fiscal years ended March 31, 2025, 2024, and 2023, the Company capitalized $7.9 million, $12.1 million, and $10.8 million respectively, in internal-use software, including $1.9 million, $3.6 million, and $3.2 million, respectively, of stock-based compensation expense. For the fiscal years ended March 31, 2025, 2024 and 2023, amortization and impairment of internal-use software was $9.0 million, $6.3 million and $4.8 million, respectively.
In addition, during the fiscal year ended March 31, 2024, the Company wrote-off $1.1 million of internal-use software related to the disposition of Lemonaid Health Limited; refer to Note 19, “Disposition of Subsidiary,” for additional information. During the fiscal years ended March 31, 2025, 2024 and 2023, the Company recorded immaterial impairment charges related to internal-use software that will not be utilized in the future.
Intangible Assets, Net
Intangible assets, net consisted of the following:
March 31, 2025
Weighted Average Remaining
Useful Life
(Years)		Gross Carrying Amount
Accumulated Amortization
Net Carrying Amount
(in thousands, except years)
Customer relationships0.0$14,900 $(14,900)$— 
Partnerships6.69,000 (3,075)5,925 
Trademark1.611,000 (7,517)3,483 
Developed technology3.624,100 (11,763)12,337 
Non-compete agreements1.62,800 (1,913)887 
Patents3.65,500 (2,797)2,703 
Total intangible assets$67,300 $(41,965)$25,335 
March 31, 2024
Weighted Average Remaining Useful
Life
(Years)		Gross Carrying Amount
Accumulated Amortization
Net Carrying Amount
(in thousands, except years)
Customer relationships0.0$14,900 $(14,900)$— 
Partnerships7.69,000 (2,175)6,825 
Trademark2.611,000 (5,317)5,683 
Developed technology4.624,100 (8,320)15,780 
Non-compete agreements2.62,800 (1,353)1,447 
Patents4.55,500 (1,980)3,520 
Total intangible assets$67,300 $(34,045)$33,255 
Amortization expense for intangible assets was $7.9 million, $12.3 million and $17.3 million for the fiscal years ended March 31, 2025, 2024 and 2023, respectively.
During the third quarter of the fiscal year ended March 31, 2023, due to decreased revenue associated with a delayed product launch and margin forecasts for the U.K. partnership business, the Company performed an interim quantitative impairment test for the U.K. partnership asset group as of December 31, 2022. The fair value of the asset group was calculated using a discounted cash flow and was determined to be lower than its carrying value. As a result, the Company recorded a $10.0 million impairment charge to write down the value of the partnership intangible asset to its estimated fair value. The charge was recorded within sales and marketing expenses in its consolidated statements of operations and comprehensive loss.
There was no impairment to intangible assets during the years ended March 31, 2025 and 2024.
Estimated future amortization expense of the identified intangible assets as of March 31, 2025 was as follows:
Estimated Amortization
(in thousands)
Fiscal years ending March 31,
2026$7,919 
20276,769 
20285,006 
20293,175 
2030993 
Thereafter1,473 
Total estimated future amortization expense$25,335 
Accrued Expense and Other Current Liabilities
Accrued expense and other current liabilities consisted of the following:
March 31, 2025March 31, 2024
(in thousands)
Accrued payables4,221 $9,623 
Accrued settlement and legal expenses1,210 3,260 
Accrued compensation and benefits3,444 3,725 
Accrued vacation68 6,528 
Accrued bonus6,123 6,588 
Accrued taxes and other433 1,108 
Total accrued expenses and other current liabilities15,499 $30,832 
Liabilities Subject to Compromise
For information regarding the components of liabilities subject to compromise, see Note 3, “Bankruptcy Proceedings.”